跳到正文
原文
MedTech Dive 器械媒体· Nick Paul Taylor·· 2026-10-08AI 评分40

Boston Scientific 任命 Joseph Fitzgerald 为首席运营官

Boston Scientific names Joseph Fitzgerald as chief operating officer

AI 导读

Boston Scientific 宣布 Joseph Fitzgerald 将于明年年初升任首席运营官,负责全球运营、业务单元与区域管理。

正文

An article from site logo

Dive Brief

Fitzgerald will oversee three newly established reportable segments as Boston Scientific works to bounce back from guidance cuts.

Published Oct. 8, 2026

By

Boston Scientific's headquarters building is shown.

Boston Scientific's headquarters is in Marlborough, Massachusetts. Courtesy of Boston Scientific

Name: Joseph Fitzgerald

New title: Chief operating officer, Boston Scientific

Previous title: Cardiovascular group president, Boston Scientific

Boston Scientific said Wednesday that it will promote Joseph Fitzgerald to chief operating officer at the start of next year.

Fitzgerald will oversee the company’s global operations, business units and regions. In connection with the appointment, Boston Scientific will establish three reportable segments, each with its own leader who will report to Fitzgerald.

Lance Bates will lead the “Interventional Therapies” segment. Boston Scientific will include Penumbra, the blood-clot removal company it is buying for $14.5 billion, in Bates’ segment. The executive’s current title is president of interventional therapies at Boston Scientific.

Nick Spadea-Anello will oversee the “Rhythm Solutions” segment. Spadea-Anello is currently president of atrial fibrillation solutions at Boston Scientific. Stephen Morse, currently president of Asia Pacific at Boston Scientific, will lead the “MedSurg” segment.

Boston Scientific CEO Mike Mahoney outlined the rationale for the move to three reportable segments.

“These changes reflect the scale and breadth of our business today and the opportunities ahead,” Mahoney said in a statement. “The new operating model will create greater capacity to focus on our long-term growth priorities while enabling our businesses to move faster and remain close to our customers and their patients.”

The changes follow a period in which Boston Scientific cut its sales guidance two quarters in a row, began a restructuring that could cost up to $800 million and experienced a cyberattack that disrupted its ability to make devices and process orders.

来源:MedTech Dive 器械媒体 · medtechdive.com